Cullinan Oncology Inc — Quarterly Cash Flow (NASDAQ:CGEM) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics

Quarterly Annual

Total assets 621.82 M579.68 M520.33 M484.13 M448.37 M Total liabilities 31.5 M27.84 M28.18 M32.76 M39.64 M Total equity 590.33 M551.84 M492.15 M451.37 M408.73 M Total liabilities & shareholders' equities 621.82 M579.68 M520.33 M484.13 M448.37 M Total debt 2.15 M———— Net debt -396.85 M————

Nouvelles

Clear Street réitère sa recommandation sur Cullinan Oncology après la validation de l’accord Gilead

Stifel relève l’objectif de cours de Cullinan Oncology suite aux progrès dans l’auto-immunité

Stifel raises Cullinan Oncology stock price target on autoimmune progress

Cullinan Therapeutics: Thesis Strengthening For T-Cell Engager Specialist (NASDAQ:CGEM)

Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

TheStreet Pro Analysts Say, “Big Tech Names are Anything But Cheap – Buy These 2 Stocks Instead” - TipRanks.com

Guggenheim initie la couverture de Cullinan Oncology avec une recommandation d’achat et un objectif de 30€

Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target

Cullinan Therapeutics Stock: Cash-Rich Biotech With Multiple Value Drivers (NASDAQ:CGEM)

Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year?

Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength

Cullinan Therapeutics prévoit des publications de données pour ses programmes d’auto-immunité